Ruben A. Mesa, MD, Chair of the Division of Hematology and Medical Oncology at the Mayo Clinic Cancer Center in Arizona, provides a discussion on molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.
ASCO Post